Australian melanoma rates take the silver – and that's good news
31 March 2016
The average risk of melanoma in Australia may have peaked in 2005 while New Zealand's rates of melanoma have risen to be the highest globally. However, Australia's burden of melanoma might stay very high over the next 15 years as the population ages. MIA Research Director Professor Mann explains.
A new study by QIMR Berghofer Medical Research Institute, one of MIA’s research affiliates, has examined melanoma rates in six different countries and used current trends to predict how they will change in coming years.
The latest data from cancer registries are from 2011. In the five years prior to that, 50 cases of melanoma occurred per 100,000 people in New Zealand while in Australia the rates fell slightly from our world-leading position in 2002-06, to 48 cases per 100,000 in 2011. Researchers predict a peak incidence of about 51 in New Zealand by 2016-2017; while in Australia rates should continue to edge down from a peak of about 49 in 2005.
Why is this happening?
The main clue is that rates of melanoma in young and middle aged Australian adults peaked in the early 2000s. This is good news because it shows that our awareness, prevention and sun protection work, especially with children in recent decades, is reaping benefits that will clearly continue in decades to come. In New Zealand the same impact has been seen in the young, but the rise of melanoma in older people has been stronger and harder to stop.
The down side of these results is that the sun exposure “banked” by people who grew up in the 1920s-1950s is still being converted into skin cancer and melanoma, especially as these generations are living longer. The total number of cases of melanoma will probably stay steady in Australia until the 2030s, but in New Zealand it is predicted to grow another 25% over 2011 levels.
So we have all been doing a pretty good job of holding this epidemic at bay, but we need to work harder with Australians over 50 (like me!). These age groups missed out on sun smart campaigns as youngsters and UV radiation has already damaged their skin badly. However, we know that our risk of melanoma and other forms of skin cancer is driven by the total dose of UV that we get throughout our life, not just when we were young. So, just as it is never too late to stop smoking, every year of good sun protection helps undo the damage done before.
Dedicated and increased prevention efforts to reduce unnecessary UV exposure remains our key weapon to fight melanoma in the future. It would be great to show by 2030 that these predictions of melanoma rates in older Australians for the 2020s were too pessimistic.
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.
Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.
Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.
It’s time again to say thank you to our amazing community fundraisers!
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.
It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.
MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.
Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.
Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.
Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.
It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.